OTCMRTSL
Market cap26kUSD
Nov 08, Last price
0.00USD
Name
Rapid Therapeutic Science Laboratories Inc
Chart & Performance
Profile
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | |||||||
Revenues | 534 -94.16% | ||||||
Cost of revenue | 1,239 | 2,115 | |||||
Unusual Expense (Income) | |||||||
NOPBT | (1,239) | (2,114) | |||||
NOPBT Margin | |||||||
Operating Taxes | (101) | 1,329 | |||||
Tax Rate | |||||||
NOPAT | (1,138) | (3,444) | |||||
Net income | (1,694) -59.65% | (4,197) 1,103.22% | |||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 585 | ||||||
BB yield | -30.67% | ||||||
Debt | |||||||
Debt current | 3,400 | 1,457 | |||||
Long-term debt | 809 | 981 | |||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | 4,588 | 2,245 | |||||
Cash flow | |||||||
Cash from operating activities | (1,152) | (2,209) | |||||
CAPEX | (39) | (293) | |||||
Cash from investing activities | (39) | (293) | |||||
Cash from financing activities | 998 | 2,195 | |||||
FCF | (1,224) | (4,099) | |||||
Balance | |||||||
Cash | (379) | 192 | |||||
Long term investments | |||||||
Excess cash | 192 | ||||||
Stockholders' equity | (10,308) | (8,328) | |||||
Invested Capital | 10,998 | 8,932 | |||||
ROIC | |||||||
ROCE | |||||||
EV | |||||||
Common stock shares outstanding | 7,747 | 7,630 | |||||
Price | 0.75 200.00% | 0.25 | |||||
Market cap | 5,810 204.62% | 1,907 | |||||
EV | 10,398 | 4,152 | |||||
EBITDA | (1,215) | (2,059) | |||||
EV/EBITDA | |||||||
Interest | 1,896 | 1,329 | |||||
Interest/NOPBT |